These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 24166908)

  • 1. Stressing the development of small molecules targeting HSP90.
    Neckers L; Trepel JB
    Clin Cancer Res; 2014 Jan; 20(2):275-7. PubMed ID: 24166908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BIIB021: A novel inhibitor to heat shock protein 90-addicted oncology.
    Yan L; Zhang W; Zhang B; Xuan C; Wang D
    Tumour Biol; 2017 Apr; 39(4):1010428317698355. PubMed ID: 28443462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HSP90 inhibitors for cancer therapy and overcoming drug resistance.
    Jhaveri K; Modi S
    Adv Pharmacol; 2012; 65():471-517. PubMed ID: 22959035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Progress in the study of heat shock protein 90 inhibitors].
    Luo HM; Sun W; Yin JY; Yang XH
    Yao Xue Xue Bao; 2010 Jul; 45(7):813-20. PubMed ID: 20931776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HSP90 inhibitors: current development and potential in cancer therapy.
    Sidera K; Patsavoudi E
    Recent Pat Anticancer Drug Discov; 2014 Jan; 9(1):1-20. PubMed ID: 23312026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rationally designed high-affinity 2-amino-6-halopurine heat shock protein 90 inhibitors that exhibit potent antitumor activity.
    Kasibhatla SR; Hong K; Biamonte MA; Busch DJ; Karjian PL; Sensintaffar JL; Kamal A; Lough RE; Brekken J; Lundgren K; Grecko R; Timony GA; Ran Y; Mansfield R; Fritz LC; Ulm E; Burrows FJ; Boehm MF
    J Med Chem; 2007 Jun; 50(12):2767-78. PubMed ID: 17488003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of 8-arylsulfanyl, 8-arylsulfoxyl, and 8-arylsulfonyl adenine derivatives as inhibitors of the heat shock protein 90.
    Llauger L; He H; Kim J; Aguirre J; Rosen N; Peters U; Davies P; Chiosis G
    J Med Chem; 2005 Apr; 48(8):2892-905. PubMed ID: 15828828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BIIB021, a novel Hsp90 inhibitor, sensitizes head and neck squamous cell carcinoma to radiotherapy.
    Yin X; Zhang H; Lundgren K; Wilson L; Burrows F; Shores CG
    Int J Cancer; 2010 Mar; 126(5):1216-25. PubMed ID: 19662650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BIIB021, an Hsp90 inhibitor: A promising therapeutic strategy for blood malignancies (Review).
    He W; Hu H
    Oncol Rep; 2018 Jul; 40(1):3-15. PubMed ID: 29749536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BIIB021, a synthetic Hsp90 inhibitor, has broad application against tumors with acquired multidrug resistance.
    Zhang H; Neely L; Lundgren K; Yang YC; Lough R; Timple N; Burrows F
    Int J Cancer; 2010 Mar; 126(5):1226-34. PubMed ID: 19676042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heat shock protein 90 inhibitor BIIB021 (CNF2024) depletes NF-kappaB and sensitizes Hodgkin's lymphoma cells for natural killer cell-mediated cytotoxicity.
    Böll B; Eltaib F; Reiners KS; von Tresckow B; Tawadros S; Simhadri VR; Burrows FJ; Lundgren K; Hansen HP; Engert A; von Strandmann EP
    Clin Cancer Res; 2009 Aug; 15(16):5108-16. PubMed ID: 19671844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting wide-range oncogenic transformation via PU24FCl, a specific inhibitor of tumor Hsp90.
    Vilenchik M; Solit D; Basso A; Huezo H; Lucas B; He H; Rosen N; Spampinato C; Modrich P; Chiosis G
    Chem Biol; 2004 Jun; 11(6):787-97. PubMed ID: 15217612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An investigation into the potential use of serum Hsp70 as a novel tumour biomarker for Hsp90 inhibitors.
    Dakappagari N; Neely L; Tangri S; Lundgren K; Hipolito L; Estrellado A; Burrows F; Zhang H
    Biomarkers; 2010 Feb; 15(1):31-8. PubMed ID: 19747088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Evaluation and Biomarker Profiling of Hsp90 Inhibitors.
    Yuno A; Lee MJ; Lee S; Tomita Y; Rekhtman D; Moore B; Trepel JB
    Methods Mol Biol; 2018; 1709():423-441. PubMed ID: 29177675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hsp90 inhibitor, BIIB021, induces apoptosis and autophagy by regulating mTOR-Ulk1 pathway in imatinib-sensitive and -resistant chronic myeloid leukemia cells.
    He W; Ye X; Huang X; Lel W; You L; Wang L; Chen X; Qian W
    Int J Oncol; 2016 Apr; 48(4):1710-20. PubMed ID: 26892093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug approval triggers debate on future direction for cancer treatments.
    Frantz S
    Nat Rev Drug Discov; 2006 Feb; 5(2):91. PubMed ID: 16521324
    [No Abstract]   [Full Text] [Related]  

  • 17. Mechanistic study on the cytostatic and tumor cell differentiation-inducing properties of 9-(2-phosphonylmethoxyethyl)adenine (PMEA, adefovir)-collected publications.
    Hatse S
    Verh K Acad Geneeskd Belg; 2000; 62(5):373-84. PubMed ID: 11144686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs.
    Roskoski R
    Pharmacol Res; 2016 May; 107():249-275. PubMed ID: 26995305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A tale of two drugs.
    Nat Rev Drug Discov; 2006 Oct; 5(10):803. PubMed ID: 17078168
    [No Abstract]   [Full Text] [Related]  

  • 20. Chelators at the cancer coalface: desferrioxamine to Triapine and beyond.
    Yu Y; Wong J; Lovejoy DB; Kalinowski DS; Richardson DR
    Clin Cancer Res; 2006 Dec; 12(23):6876-83. PubMed ID: 17145804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.